期刊
EUROSURVEILLANCE
卷 25, 期 42, 页码 18-23出版社
EUR CENTRE DIS PREVENTION & CONTROL
DOI: 10.2807/1560-7917.ES.2020.25.41.2001721
关键词
-
资金
- NIHR Oxford Biomedical Research Centre
- von Opel Foundation award
- Wellcome intermediate fellowship [110110/Z/15/Z]
- Wellcome Trust [102176/B/13/Z, WT109965MA]
- Medical Research Foundation [MRF-1450004]
- Kennedy Trust for Rheumatology Research
- SGC, a registered charity from AbbVie [1097737]
- Bayer Pharma AG
- Boehringer Ingelheim
- Canada Foundation for Innovation
- Eshelman Institute for Innovation
- Genome Canada through Ontario Genomics Institute [OGI-055]
- Innovative Medicines Initiative (EU/EFPIA) [EUbOPEN grant] [875510]
- Janssen
- Merck KGaA, Darmstadt, Germany
- MSD
- Novartis Pharma AG
- Pfizer
- Sao Paulo Research Foundation-FAPESP
- Takeda
- Wellcome
- NIHR Senior Fellowship
- MRC [MR/N00065X/1, MC_UU_00008/6] Funding Source: UKRI
SARS-CoV-2 IgG screening of 1,000 antenatal serum samples in the Oxford area, United Kingdom, between 14 April and 15 June 2020, yielded a 5.3% seroprevalence, mirroring contemporaneous regional data. Among the 53 positive samples, 39 showed in vitro neutralisation activity, correlating with IgG titre (Pearson's correlation p<0.0001). While SARS-COV-2 seroprevalence in pregnancy cohorts could potentially inform population surveillance, clinical correlates of infection and immunity in pregnancy, and antenatal epidemiology evolution over time need further study.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据
分享论文
